TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent/assent for study participation obtained before undergoing any study-specific procedures~* Documented congenital FXIII deficiency which requires prophylactic treatment with a FXIII containing product.~* Males and females of any age with congenital FXIII deficiency~* Received full hepatitis B vaccination and/or is hepatitis B surface antibody positive~Exclusion Criteria:~* Diagnosis of acquired FXIII deficiency~* Administration of a FXIII-containing product, including blood transfusions or other blood products within 4 weeks prior to the planned Day 0~* Any known congenital or acquired coagulation disorder other than congenital FXIII deficiency~* Known or suspected to have antibodies towards FXIII~* Use of any other investigational medicinal product within 4 weeks prior to the Baseline Visit (Day 0)~* Known Positivity for human immunodeficiency virus (HIV) or a positive result for HIV at the Screening Visit of this study or the FXIII study 2002 (NCT00883090).~* Serum aspartate transaminase (AST) or serum alanine transaminase (ALT) concentration \>2.5 times the upper limit of normal at the Screening Visit of this study or at the Day 56 Visit of Factor XIII Study BI71023_2002 (NCT00883090)~* Fibrinogen level less than 85% of the lower limit of normal at the Screening Visit of this study or the Factor XIII Study BI71023_2002 (NCT00883090)~* Active bleeding ≥ Common Terminology Criteria for Adverse Events (CTCAE) Grade 2 and/or ≥ moderate between the Screening and Baseline Visits~* Pregnant or breast-feeding~* Intention to become pregnant during the course of the study~* Female subjects of childbearing potential not using, or not willing to use, a medically reliable method of contraception for the entire duration of the study~* Suspected inability (e.g., language problems) or unwillingness to comply with study procedures or history of noncompliance

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FXIII (Type: EXPERIMENTAL): All subjects who received a dose of Factor XIII (FXIII) Concentrate (Human).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study in Maintenance Kidney Transplant Recipients Following Conversion to Nulojix® (Belatacept)-Based

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Men and women, ages 18-75 inclusive~* Adult recipients of a renal allograft from a living donor or a deceased donor between 6-60 months prior to enrollment~* Receiving a stable (≥1 month) regimen of Calcineurin inhibitor (CNI) \[Cyclosporine A (CsA) or Tacrolimus (TAC)\] with Mycophenolate mofetil (MMF) or Enteric Coated Mycophenolate Sodium (EC-MPS)/Mycophenolic acid (MPA), and corticosteroids~* Stable renal function for 12 weeks prior to enrollment without new onset proteinuria~* Calculated glomerular filtration rate (cGFR) ≥30 and ≤75 mL/min/1.73 m2 \[Modification of Diet in Renal Disease study (MDRD) 4-formula\]~Exclusion Criteria:~* Recipients with Epstein-Barr virus (EBV) serostatus negative or unknown~* History of acute rejection (AR) within 3 months prior to enrollment~* History of antibody mediated rejection~* Positive T-cell lymphocytotoxic cross match~* Proteinuria \>1 g/day or \>0.5 g/day if diabetic

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Belatacept (Type: EXPERIMENTAL): Belatacept 5 mg/kg intravenous 30 minute infusion on Days 1, 15, 29, 43, 57 then every 28 days for 24 months
- CNI (Type: ACTIVE_COMPARATOR): Tacrolimus 4-11 ng/mL tablet orally according to package insert for 24 months~Cyclosporine 50-250 ng/mL tablet orally according to package insert for 24 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clonidine as Adjunct Therapy for the Treatment of Neonatal Abstinence Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
* neonates born at gestational age of 35 weeks or greater~* neonates aged 0 to 14 days~* prenatally exposed to opioids~* severe NAS defined as 2 consecutive modified Finnegan Scores (MFS) \> or = 9~Exclusion Criteria:~* \< 35 weeks gestational age~* Intrauterine growth retardation defined as \<5%tile of gestational age~* postnatal treatment with barbiturates or benzodiazepines,~* major congenital anomalies~* major concomitant medical illness requiring oxygen therapy, intravenous fluids or medications.~* breastfed infants

- Gender: ALL
- Minimum Age: None
- Maximum Age: 14 Days
- Healthy Volunteers: f

Study Arms:
- Clonidine treatment (Type: EXPERIMENTAL): Infants intrauterine exposed to opioids (heroin or methadone) that demonstrate signs and symptoms of withdrawal with withdrawal scores (modified Finnegan score) greater than 9 on to consecutive scores taken 4 hours apart.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Can Adequacy of Anesthesia Depth and Quality of Recovery be Influenced by the Level of Neuromuscular Blockade?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients ASA I-III~* Between 18 - 80 years old~* Scheduled for routine cervical surgery~* Minimum duration of surgery is 90 minutes and performed with total intravenous anaesthesia (TIVA) with the hypnotic propofol, the analgesic remifentanil and the neuromuscular relaxant rocuronium~* Patients that are able to and do provide a signed informed consent form~Exclusion Criteria:~* Patients with neuromuscular diseases and severe cardiac and respiratory pathologies~* Contra indication for any of the drugs used~* Not able to complete the baseline PQRS test.~* Indication to perform tracheal intubation using fibroscopy~* Patients who are pregnant or nursing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Standard Group (Type: NO_INTERVENTION): Standard Clinical Practice Group - standard neuromuscular block, with a standard rocuronium dose for intubation (0.6 mg/kg). If required, the reversal of neuromuscular block is performed with neostigmine.
- Deep NMB group (Type: EXPERIMENTAL): Deep Neuromuscular Block group - with a standard rocuronium dose for intubation (0.6 mg/kg), followed by a constant infusion of rocuronium (10-15 ug/kg/min) to guarantee a PTC less or equal to 2 on the TOF monitor (PTC is evaluated every 5 minutes). The reversal of neuromuscular block is performed with Sugammadex (4 mg/kg).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Larval Debridement Therapy Versus Sharp Debridement to Remove Biofilm

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Veterans over 21 years of age~* with chronic lower extremity or diabetic foot ulcers (wound duration over 8 weeks)~* who at the clinician's judgment requires wound debridement (25% or more of wound bed covered with non-viable tissue)~* wound size 1.5 cm (roughly the size of a quarter) or larger in diameter~Exclusion Criteria:~* Cognitive impairment that would interfere with patient signing own Informed Consent~* Veterans on active anticoagulant therapy with most recent (within last week) PT/INR (international normalized ratio of prothrombin time) \> 3.0, or other significant bleeding risk~* Active immune suppression just prior to or during study (on systemic corticosteroids\* within 7 days prior, or chemotherapy for cancer or RA treatment within 4 weeks prior to study, or with diagnosis of HIV/AIDS) - \*Nasal steroid sprays will not be excluded~* Active systemic antibiotics is an exclusion~* Absent dorsalis pedis pulses and Ankle Brachial Index (ABI) \< 0.5 is an exclusion (indicates critical limb ischemia).~* Other possible reasons participants could be removed from this study include: transfers to other non-VA facilities, participant is unable to tolerate tissue sampling even with local anesthesia, and/or inability to comply with scheduled research visits. Furthermore, if the participant has significant wound healing so that sampling is not possible after the initial sampling, they will be removed from the study.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Larval Debridement Therapy (Type: ACTIVE_COMPARATOR): Larval debridement therapy intervention (Biobags) filled with sterile green bottle fly maggots (larvae) placed in open, chronic lower extremity or diabetic foot ulcer once every 4 days for total of 2 applications over the 8 day study period.
- Sharp Debridement Therapy (Type: ACTIVE_COMPARATOR): Bedside sharp debridement therapy as a comparator performed by wound care clinician once every 7 days in a chronic lower extremity or diabetic foot ulcer for a total of 2 sharp debridements over the 8 day study period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Japanese Phase 1 Trial of Sym004 in Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Japanese male or female subjects aged greater than or equal to 20 years at the time of informed consent signature~* Histologically or cytologically confirmed cancer~* Refractory or recurrent advanced late stage solid tumors without available therapeutic options which are likely to provide patient benefit (failure and/or intolerance to standard anti-cancer therapy)~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~* Life expectancy of at least 3 months~* Written informed consent given before any trial-related activities are carried out~* Other protocol defined inclusion criteria could apply~Exclusion Criteria:~* Subjects with symptomatic brain metastases~* Subjects who received total resection or irradiation of the target lesion~* Received any of the following medications within 4 weeks before the first administration of Sym004 at Week 1: cytotoxic or cytostatic anti-cancer therapy, antibody therapy, tyrosine kinase inhibitors, and any investigational agent~* Received vaccine therapy as anticancer treatment within 12 weeks before the first administration of Sym004 at Week 1~* Diarrhea of greater than Grade 1 according to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03 (v4.03)~* Skin manifestation of greater than Grade 1 according to NCI-CTCAE (v4.03)~* Magnesium of less than 0.9 milligram per deciliter (mg/dL)~* Abnormal organ or bone marrow function as defined in the protocol~* Received immunosuppressive agents (including systemic corticosteroids used at doses above 20 milligram per day (mg/day) of prednisolone or equivalent) within 4 weeks before the first administration of Sym004 at Week 1~* Active severe infection, any other concurrent disease or medical conditions that are deemed to interfere with the conduct of the trial as judged by the Investigator~* Known human immunodeficiency virus (HIV) positive, active Hepatitis B or C, or uncontrolled allergic conditions or allergy to Sym004 or its components~* Clinically significant cardiac disease or concurrent, uncontrolled medical condition~* Known previous Grade 3 to 4 infusion-related reactions, according to NCI-CTCAE (v4.03), with chimeric monoclonal antibodies~* Other protocol defined exclusion criteria could apply

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sym004 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: AIM to Improve Asthma: Airflow Improvements During Meal-Prep

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Household has a gas stove~* Household has a range hood that vents to the outdoors~* Household in Richmond or San Pablo~Exclusion Criteria:~* Child has other significant medical illnesses (e.g. prematurity, diabetes)~* living with a smoker who smokes indoors~* family knows they will not have stable housing for the period of the study~* Parent is not fluent in English.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Intervention after One Week (Type: OTHER): This arm will have baseline data on air pollutant levels, stove use and range hood use collected for one week prior to receiving an educational intervention aimed at increasing use of the range hood. Data following the intervention will be collected for an additional week.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of PCV13 and Fluad in Adults Aged ≥60 Years

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adults aged ≥60 years who signed the informed consent~Exclusion Criteria:~* Previous pneumococcal vaccine recipients~* Egg allergy~* History of serious adverse event after vaccination,~* any acute disease or infection~* History of neurological symptoms or signs~* Impairment of immune function or immunosuppressant use~* Bleeding diathesis~* Fever (defined as axillary temperature ³38.0°C) within 3 days (prior to Visit 1)

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- PCV13 and Fluad (Type: ACTIVE_COMPARATOR): 437 concomitant Fluad-PCV13 recipients: one dose of each vaccine administered on Day 0
- Fluad alone (Type: ACTIVE_COMPARATOR): 437 Fluad recipients: one vaccine injection administered on Day 0
- PCV13 alone (Type: ACTIVE_COMPARATOR): 437 PCV13 recipients: one vaccine injection administered on Day 0

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Non-surgical Step 3 Periodontal Treatment With/Without Adjunctive Protocol - Pilot RCT.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* systemically healthy individuals, smokers and non-smokers, HbA1c \<7.5%, compliant and adhering to systematic periodontal treatment protocol incl. SPT visits, patients willing to complete a 9-month post-op observation period~Exclusion Criteria:~* rheumatoid arthritis, HbA1c ≥7.5%, treatment of periodontitis within past 12 months, use of systemic antibiotics in past 6 months, pregnant and lactating individuals

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Group A (Type: EXPERIMENTAL): Test arm, patients undergo subgingival instrumentation of residual active site together with an adjunctive treatment protocol.
- Group B (Type: PLACEBO_COMPARATOR): Control arm, patients undergo subgingival instrumentation of residual active site only.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: DATAS: The Dual Chamber & Atrial Tachyarrhythmias Adverse Events Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Meet the Class I implantation criteria for single chamber implantable cardioverter defibrillator according to the guidelines (ACC/AHA).~Exclusion Criteria:~* Permanent atrial fibrillation~* Patients without structural heart disease~* Patient meets implantation criteria for dual-chamber pacing (symptomatic sinus node disease, all 2nd Atrio-Ventricular (AV) block \[except asymptomatic Mobitz I\] and all 3rd degree AV block ).~* Patient with previous system implanted (ICD or pacemaker).~* Patients with biventricular stimulation or re-synchronization.~* Patient has a mechanical right heart valve.~* Patient has medical conditions that would preclude the testing required by the protocol, or limit study participation.~* Patient is unwilling or unable to cooperate or give written informed consent, or the patient is a minor and legal guardians refuse to give informed consent.~* Patient is or will be inaccessible for follow-up at the study center.~* Patients who are enrolled or planning to enroll in other clinical trials during the clinical study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- SC true (Type: ACTIVE_COMPARATOR): Single chamber Implantable Cardioverter Defibrillator programmed as a Single Chamber.
- SC sim (Type: EXPERIMENTAL): Dual chamber ICD initially programmed as single chamber (SC simulated) ICD (''SC sim arm'')
- DC true (Type: EXPERIMENTAL): Dual chamber ICD initially programmed as a DDED (''DC true arm'').

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Fazirsiran (TAK-999, ARO-AAT) in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATD)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of AATD~* Women of childbearing potential must have a negative pregnancy test, cannot be breast feeding, and must be willing to use contraception~* Willing to provide written informed consent and to comply with study requirements~* Non-smoker for at least 1 year~* No abnormal finding of clinical relevance at screening~Exclusion Criteria:~* Clinically significant health concerns other than AATD~* Previous diagnosis or diagnosis at Screening of definitive liver cirrhosis~* Regular use of alcohol within one month prior to Screening~* Use of an investigational agent or device within 30 days prior to dosing or current participation in an investigational study involving therapeutic intervention~* Use of illicit drugs within 1 year prior to Screening~Note: additional inclusion/exclusion criteria may apply, per protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Fazirsiran (TAK-999, ARO-AAT) Cohort 1 (Type: EXPERIMENTAL): Administered on Day 1, Weeks 4 and 16 for a minimum of 3 doses.~Treatment Extension (optional enrollment): Administered every 12 weeks for 12 additional doses.
- Fazirsiran (TAK-999, ARO-AAT) Cohort 1b (Type: EXPERIMENTAL): Administered on Day 1, Weeks 4 and 16, for a minimum of 3 doses.~Treatment Extension (optional enrollment): Administered every 12 weeks for 12 additional doses.
- Fazirsiran (TAK-999, ARO-AAT) Cohort 2 (Type: EXPERIMENTAL): Administered on Day 1, Weeks 4, 16, 28 and 40 for a minimum of 5 doses.~Treatment Extension (optional enrollment): Administered every 12 weeks for 12 additional doses.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete